Disclosures for "RAG-17, a Novel siRNA Therapy for SOD1-ALS: Safety and Preliminary Efficacy from a First-in-human Trial"
-
The institution of Dr. ye has received research support from Ractigen Therapeutics, Suzhou, China.
-
Dr. Jiang has nothing to disclose.
-
Miss wang has nothing to disclose.
-
Dr. pan has nothing to disclose.
-
The institution of Dr. Wang has received research support from Ractigen Therapeutics, Suzhou,China.
-
Mr. Qu has received research support from Ractigen Therapeutics, Suzhou,China.
-
Dr. liao has received research support from Ractigen Therapeutics, Suzhou,China.
-
The institution of Miss zhou has received research support from Ractigen Therapeutics, Suzhou,China.
-
Ms. Zhang has nothing to disclose.
-
Dr. Kang has nothing to disclose.
-
Dr. Li has stock in Ractigen Therapeutics. Dr. Li has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. chen has received research support from Ractigen Therapeutics, Suzhou,China.
-
The institution of Dr. Wang has received research support from Ractigen Therapeutics, Suzhou, China. The institution of Dr. Wang has received research support from the National Natural Science Foundation of China. The institution of Dr. Wang has received research support from Capital's Funds for Health Improvement and Research. The institution of Dr. Wang has received research support from National Key R&D Program of China. The institution of Dr. Wang has received research support from Beijing Laboratory of Oral Health. The institution of Dr. Wang has received research support from Beijing Municipal Science & Technology Commission.